1. Lenders, J.W., et al., Phaeochromocytoma. Lancet, 2005. 366(9486): p. 665-75.
2. Lenders, J.W., et al., Biochemical diagnosis of pheochromocytoma: which test is best? JAMA, 2002. 287(11): p. 1427-34.
3. Eisenhofer, G., J.W. Lenders, and K. Pacak, Biochemical diagnosis of pheochromocytoma. Front Horm Res, 2004. 31: p. 76-106.
4. Elder, E.E., G. Elder, and C. Larsson, Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol, 2005. 89(3): p. 193-201.
5. Manger, W.M. and R.W. Gifford, Pheochromocytoma. J Clin Hypertens, 2002. 4(1): p. 62-72.
6. Bravo, E., Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev, 1994. 15(3): p. 356-368.
7. Mantero, F., et al., A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab, 2000. 85(2): p. 637-44.
8. Whalen, R.K., A.F. Althausen, and G.H. Daniels, Extra-adrenal pheochromocytoma. J Urol, 1992. 147(1): p. 1-10.
9. O'Riordain, D.S., et al., Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg, 1996. 20(7): p. 916-21.
10. Remine, W., et al., Current management of pheochromocytoma. Ann Surg, 1974. 179: p. 740-748.
11. Klingler, H.C., et al., Pheochromocytoma. Urology, 2001. 57(6): p. 1025-32.
12. Pacak, K., et al., Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med, 2001. 134(4): p. 315-29.
13. Manger, W.M. and R.W. Gifford, Clinical and Experimental Pheochromocytoma. 2nd ed. 1996, Cambridge, MA: Blackwell Science.
14. Streeten, D.H. and G.H. Anderson, Jr., Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am J Hypertens, 1996. 9(8): p. 760-9.
15. Bravo, E.L. and R.W. Gifford, Jr., Pheochromocytoma. Endocrinol Metab Clin North Am, 1993. 22(2): p. 329-41.
16. Bravo, E.L. and R. Tagle, Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev, 2003. 24(4): p. 539-53.
17. Manger, W. and R. Gifford, Clinical and Experimental Pheochromocytoma. Blackwell Science, Cambridge, Massachusetts. 1996.
18. Ram, C.V. and G.A. Fierro-Carrion, Pheochromocytoma. Semin Nephrol, 1995. 15(2): p. 126-37.
19. Steen, R.E., et al., In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol (Copenh), 1991. 125: p. 331-334.
20. Bouloux, P.G. and M. Fakeeh, Investigation of phaeochromocytoma. Clin Endocrinol (Oxf), 1995. 43(6): p. 657-64.
21. Timmers, H.J., et al., Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab, 2007. 92(3): p. 779-86.
22. Kuchel, O., Pseudopheochromocytoma. Hypertension, 1985. 7(1): p. 151-8.
23. Kuchel, O., New Insights Into Pseudopheochromocytoma and Emotionally Provoked Hypertension, in Secondary Hypertension, G.A. Mansoor, Editor. 2004, Humana Press: Totowa. p. in press.
24. Ladroue, C., et al., PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med, 2008. 359(25): p. 2685-92.
25. Hao, H.X., et al., SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 2009. 325(5944): p. 1139-42.
26. Neumann, H.P., et al., Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med, 2002. 346(19): p. 1459-66.
27. Mannelli, M., et al., Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab, 2009. 94(5): p. 1541-7.
28. Pacak, K., et al., Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med, 2005. 257(1): p. 60-8.
29. Mulligan, L., et al., Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics, 1994. 6(1): p. 70-74.
30. Schuffenecker, I., et al., RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet, 1994. 3(11): p. 1939-43.
31. Carlson, K.M., et al., Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A, 1994. 91(4): p. 1579-83.
32. Eng, C., et al., Point mutation within the tyrosine kinase domain of the RET proto- oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet, 1994. 3(2): p. 237-41.
33. Mulligan, L.M., et al., Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med, 1995. 238(4): p. 343-6.
34. Karsdorp, N., et al., Von Hippel-Lindau disease: new strategies in early detection and treatment. Am J Med, 1994. 97(2): p. 158-68.
35. Koch, C.A., et al., Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. Oncogene, 2002. 21(3): p. 479-82.
36. Lamiell, J.M., F.G. Salazar, and Y.E. Hsia, von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore), 1989. 68(1): p. 1-29.
37. Linehan, W., M. Lerman, and B. Zbar, Identification of the VHL Gene: Its Role in Renal Carcinoma. JAMA, 1995. 273: p. 564-570.
38. Brauch, H., et al., Von Hippel Lindau (VHL) disease with pheochromocytoma in the Black forest region of Germany: evidence for a founder effect. Hum Genet, 1995. 95(5): p. 551-556.
39. Huson, S.M., et al., A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet, 1989. 26(11): p. 704-11.
40. Riccardi, V.M., Neurofibromatosis: past, present, and future. N Engl J Med, 1991. 324(18): p. 1283-5.
41. Astuti, D., et al., Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet, 2001. 69(1): p. 49-54.
42. Baysal, B.E., et al., Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000. 287(5454): p. 848-51.
43. Baysal, B.E., et al., Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet, 2002. 39(3): p. 178-83.
44. Schiavi, F., et al., Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. Jama, 2005. 294(16): p. 2057-63.
45. Amar, L., et al., Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol, 2005. 23(34): p. 8812-8.
46. Gimenez-Roqueplo, A.P., et al., Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res, 2003. 63(17): p. 5615-21.
47. Neumann, H.P., et al., Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA, 2004. 292(8): p. 943-51.
48. Benn, D.E., et al., Clinical presentation and penetrance of Pheochromocytoma/ Paraganglioma syndromes. J Clin Endocrinol Metab, 2005.
49. Young, A.L., et al., Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab, 2002. 87(9): p. 4101-5.
50. Brouwers, F.M., et al., High Frequency of SDHB Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. J Clin Endocrinol Metab, 2006. 91(11): p. 4505-9.
51. Ghayee, H.K., et al., Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocr Relat Cancer, 2009. 16(1): p. 291-9.
52. Bryant, J., et al., Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst, 2003. 95(16): p. 1196-204.
53. Dahia, P.L., et al., Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res, 2005. 65(21): p. 9651-8.
54. Eisenhofer, G., Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats. Naunyn Schmiedebergs Arch Pharmacol, 1994. 349: p. 259-269.
55. Eisenhofer, G., The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther, 2001. 91(1): p. 35-62.
56. Eisenhofer, G., Editorial: biochemical diagnosis of pheochromocytoma--is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab, 2003. 88(2): p. 550-2.
57. Eisenhofer, G., et al., Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol, 2003: p. 'in press'.
58. Eisenhofer, G., et al., Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord, 2001. 2(3): p. 297-311.
59. Eisenhofer, G., et al., Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab, 1998. 83(6): p. 2175-85.
60. Eisenhofer, G., et al., Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med, 1999. 340: p. 1872-1879.
61. Eisenhofer, G., J.W. Lenders, and K. Pacak, Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines. Curr Hypertens Rep, 2002. 4(3): p. 250-5.
62. Sawka, A.M., et al., The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab, 2004. 89(6): p. 2859-66.
63. Sawka, A.M., et al., A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab, 2003. 88(2): p. 553-8.
64. Unger, N., et al., Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol, 2006. 154(3): p. 409-17.
65. Eisenhofer, G., et al., Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab, 2003. 88(6): p. 2656-66.
66. Lenders, J.W., et al., Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. 95(1): p. 238-45.
67. Eisenhofer, G., et al., Plasma metanephrines in renal failure. Kidney Int, 2005. 67(2): p. 668-77.
68. Timmers, H., et al., Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer, 2009.
69. Eisenhofer, G., et al., Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab, 2005. 90: p. 2086-2075.
70. Timmers, H.J. and K. Pacak, Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. Expert Review of Endocrinology and Metabolism, 2007. 2(3): p. 399-406.
71. Ilias, I. and K. Pacak, Current approaches and recommended algorithm for the diagnostic localization of pheohcromocytoma. J Clin Endocrinol Metab, 2004. 89.
72. Furuta, N., et al., Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol, 1999. 6(3): p. 119-24.
73. van der Harst, E., et al., [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab, 2001. 86(2): p. 685-93.
74. Ilias, I., B. Shulkin, and K. Pacak, New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab, 2005. 16(2): p. 66-72.
75. Timmers, H.J., et al., Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab, 2009.
76. Pacak, K., G. Eisenhofer, and D.S. Goldstein, Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev, 2004. 25(4): p. 568-80.
77. Pacak, K., et al., 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension, 2001. 38(1): p. 6-8.
78. Ilias, I., et al., Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab, 2003. 88(9): p. 4083-7.
79. Hoegerle, S., et al., 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging, 2003. 30(5): p. 689-94.
80. Hoegerle, S., et al., Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology, 2002. 222(2): p. 507-12.
81. Shulkin, B.L., et al., Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET. Nucl Med, 1999. 212: p. 35-41.
82. Shulkin, B.L., et al., PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med, 1992. 33: p. 1125-1131.
83. Mann, G.N., et al., [(11)C]metahydroxyephedrine and [(18)f]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol, 2006. 13(2): p. 187-97.
84. Mamede, M., et al., Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun, 2006. 27(1): p. 31-6.
85. Timmers, H.J., et al., Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol, 2007. 25(16): p. 2262-9.
86. Pacak, K., H. Keiser, and G. Eisenhofer, Pheochromocytoma, in Textbook of Endocrinology, L.S. De Groot and J.L. Jameson, Editors. 2005, Elsevier Saunders: Philadelphia. p. 2501-2534.
87. Brouwers, F.M., et al., Pheochromocytoma as an endocrine emergency. Rev Endocr Metab Disord, 2003. 4(2): p. 121-8.
88. Pacak, K., et al., Pheochromocytoma: progress in diagnosis, therapy, and genetics., in Adrenal Disorders, A. Margioris and G.P. Chrousos, Editors. 2001, Humana Press: Totowa. p. 479-523.
89. Eisenhofer, G., et al., Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf, 2007. 30(11): p. 1031-62.
90. Pacak, K., Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab, 2007. 92(11): p. 4069-79.
91. Goldstein, R.E., et al., Clinical experience over 48 years with pheochromocytoma. Ann Surg, 1999. 229(6): p. 755-64.
92. John, H., et al., Pheochromocytomas: can malignant potential be predicted? Urology, 1999. 53(4): p. 679-83.
93. Proye, C.A., et al., "The" pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg, 1994. 18(4): p. 467-72.
94. Yu, J. and K. Pacak, Metastatic pheochromocytoma. Endocrinologist, 2002. 12: p. 291-299.
95. Mundschenk, J. and H. Lehnert, Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes, 1998. 106(5): p. 373-6.
96. Huang, H., et al., Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer, 2008. 113(8): p. 2020-8.
97. Averbuch, S.D., et al., Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med, 1988. 109(4): p. 267-73.
98. He, J., et al., Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine, 2009. 36(2): p. 189-93.
99. Gonias, S., et al., Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol, 2009. 27(25): p. 4162-8.
100. Loh, K.C., et al., The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest, 1997. 20(11): p. 648-58.
101. Kopf, D., et al., Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf), 1997. 46(1): p. 39-44.
102. Adjalle, R., et al., Treatment of malignant pheochromocytoma. Horm Metab Res, 2009. 41(9): p. 687-96.
103. Werbel, S.S. and K.P. Ober, Pheochromocytoma. Update on diagnosis, localization, and management. Med Clin North Am, 1995. 79(1): p. 131-53.
104. Calandra, R.S., et al., Hormonal and metabolic studies in pheochromocytoma. Can Med Assoc J, 1970. 102(13): p. 1369-72.
105. Eisenhofer, G. and K. Pacak, Diagnosis of pheochromocytoma, in Harrison’s Textbook Online 2004.